Randomized trial of mechanotherapy for the treatment of stress urinary incontinence in women

Background: Stress urinary incontinence (SUI) presents as unintentional urine leakage associated with activities. It significantly affects quality of life (QoL) and is the most common type of incontinence in women. Current treatment options, particularly non-surgical therapies, are lacking. Objectiv...

Full description

Bibliographic Details
Main Authors: Nissrine Nakib, Suzette Sutherland, Kevin Hallman, Marcus Mianulli, David R Boulware
Format: Article
Language:English
Published: SAGE Publishing 2024-02-01
Series:Therapeutic Advances in Urology
Online Access:https://doi.org/10.1177/17562872241228023
_version_ 1797321640590180352
author Nissrine Nakib
Suzette Sutherland
Kevin Hallman
Marcus Mianulli
David R Boulware
author_facet Nissrine Nakib
Suzette Sutherland
Kevin Hallman
Marcus Mianulli
David R Boulware
author_sort Nissrine Nakib
collection DOAJ
description Background: Stress urinary incontinence (SUI) presents as unintentional urine leakage associated with activities. It significantly affects quality of life (QoL) and is the most common type of incontinence in women. Current treatment options, particularly non-surgical therapies, are lacking. Objective: To assess the efficacy of mechanotherapy provided by the Flyte ® intra-vaginal device during pelvic floor muscle training (PFMT). Design: This was a randomized, controlled, double-blinded trial. Materials and methods: Flyte is a repeat use device for conditioning and strengthening the pelvic floor muscles (PFMs). It provides two-part mechanotherapy. Part 1 is the stretching and preloading of the PFM from the internal wand. Part 2 integrates mechanical pulses which elicit muscle cellular and tissue level responses that trigger cellular regeneration, improve neuromuscular facilitation and motor learning. Subjects used the device for 5 min/day for 12 weeks. Subjects (144) were randomized and evaluated at 6 and 12 weeks. Arm A (72) received both Part 1 and Part 2 mechanotherapy for 12 weeks, whereas Arm B (72) received Part 1 therapy for 6 weeks, then crossed over to full therapy. Mean age was 50, 49, respectively, prior pelvic/abdominal surgery 26%, 46%, and previous incontinence treatments 13%, 22%. The primary endpoint was 24-h pad weight (24-HR PW) at 6 weeks. Secondary endpoints were 24-HR PW at 12 weeks and QoL [International Consultation on Incontinence Questionnaire (ICIQ), Urinary Incontinence Quality of Life (IQOL)]. Results: Part 1 therapy had a greater than anticipated therapeutic effect. Thus, the study was underpowered to identify differences between study arms. Therefore, data were pooled to assess the effects of mechanotherapy. Twenty four-HR PW was significantly reduced at 6 weeks ( p  = <0.0001), with further reduction from 6 to 12 weeks ( p  = <0.0001). Data were stratified based on 24-HR PW severity. Significant reductions were noted in all severity groups (mild p  = <0.0001, moderate p  = <0.0001, severe p  = <0.01). QoL was similarly improved at 6 weeks (ICIQ p  = <0.0001, IQOL p  = <0.0001), and 12 weeks (ICIQ p  = <0.0001, IQOL p  = <0.0001). Compliance was >80% at 6 weeks and 70% at 12 weeks. Conclusion: Two-part mechanotherapy significantly improved 24-HR PW and QoL across all severities of SUI. Improvements were noted in as little as 2 weeks and appeared to be sustained through 2-year follow up. Trial registration: Registered on ClinTrials.gov (NCT02954042).
first_indexed 2024-03-08T05:02:29Z
format Article
id doaj.art-7b14ac84aa904eb2b980710ab387373e
institution Directory Open Access Journal
issn 1756-2880
language English
last_indexed 2024-03-08T05:02:29Z
publishDate 2024-02-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Urology
spelling doaj.art-7b14ac84aa904eb2b980710ab387373e2024-02-07T11:03:48ZengSAGE PublishingTherapeutic Advances in Urology1756-28802024-02-011610.1177/17562872241228023Randomized trial of mechanotherapy for the treatment of stress urinary incontinence in womenNissrine NakibSuzette SutherlandKevin HallmanMarcus MianulliDavid R BoulwareBackground: Stress urinary incontinence (SUI) presents as unintentional urine leakage associated with activities. It significantly affects quality of life (QoL) and is the most common type of incontinence in women. Current treatment options, particularly non-surgical therapies, are lacking. Objective: To assess the efficacy of mechanotherapy provided by the Flyte ® intra-vaginal device during pelvic floor muscle training (PFMT). Design: This was a randomized, controlled, double-blinded trial. Materials and methods: Flyte is a repeat use device for conditioning and strengthening the pelvic floor muscles (PFMs). It provides two-part mechanotherapy. Part 1 is the stretching and preloading of the PFM from the internal wand. Part 2 integrates mechanical pulses which elicit muscle cellular and tissue level responses that trigger cellular regeneration, improve neuromuscular facilitation and motor learning. Subjects used the device for 5 min/day for 12 weeks. Subjects (144) were randomized and evaluated at 6 and 12 weeks. Arm A (72) received both Part 1 and Part 2 mechanotherapy for 12 weeks, whereas Arm B (72) received Part 1 therapy for 6 weeks, then crossed over to full therapy. Mean age was 50, 49, respectively, prior pelvic/abdominal surgery 26%, 46%, and previous incontinence treatments 13%, 22%. The primary endpoint was 24-h pad weight (24-HR PW) at 6 weeks. Secondary endpoints were 24-HR PW at 12 weeks and QoL [International Consultation on Incontinence Questionnaire (ICIQ), Urinary Incontinence Quality of Life (IQOL)]. Results: Part 1 therapy had a greater than anticipated therapeutic effect. Thus, the study was underpowered to identify differences between study arms. Therefore, data were pooled to assess the effects of mechanotherapy. Twenty four-HR PW was significantly reduced at 6 weeks ( p  = <0.0001), with further reduction from 6 to 12 weeks ( p  = <0.0001). Data were stratified based on 24-HR PW severity. Significant reductions were noted in all severity groups (mild p  = <0.0001, moderate p  = <0.0001, severe p  = <0.01). QoL was similarly improved at 6 weeks (ICIQ p  = <0.0001, IQOL p  = <0.0001), and 12 weeks (ICIQ p  = <0.0001, IQOL p  = <0.0001). Compliance was >80% at 6 weeks and 70% at 12 weeks. Conclusion: Two-part mechanotherapy significantly improved 24-HR PW and QoL across all severities of SUI. Improvements were noted in as little as 2 weeks and appeared to be sustained through 2-year follow up. Trial registration: Registered on ClinTrials.gov (NCT02954042).https://doi.org/10.1177/17562872241228023
spellingShingle Nissrine Nakib
Suzette Sutherland
Kevin Hallman
Marcus Mianulli
David R Boulware
Randomized trial of mechanotherapy for the treatment of stress urinary incontinence in women
Therapeutic Advances in Urology
title Randomized trial of mechanotherapy for the treatment of stress urinary incontinence in women
title_full Randomized trial of mechanotherapy for the treatment of stress urinary incontinence in women
title_fullStr Randomized trial of mechanotherapy for the treatment of stress urinary incontinence in women
title_full_unstemmed Randomized trial of mechanotherapy for the treatment of stress urinary incontinence in women
title_short Randomized trial of mechanotherapy for the treatment of stress urinary incontinence in women
title_sort randomized trial of mechanotherapy for the treatment of stress urinary incontinence in women
url https://doi.org/10.1177/17562872241228023
work_keys_str_mv AT nissrinenakib randomizedtrialofmechanotherapyforthetreatmentofstressurinaryincontinenceinwomen
AT suzettesutherland randomizedtrialofmechanotherapyforthetreatmentofstressurinaryincontinenceinwomen
AT kevinhallman randomizedtrialofmechanotherapyforthetreatmentofstressurinaryincontinenceinwomen
AT marcusmianulli randomizedtrialofmechanotherapyforthetreatmentofstressurinaryincontinenceinwomen
AT davidrboulware randomizedtrialofmechanotherapyforthetreatmentofstressurinaryincontinenceinwomen